⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TAK News
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda présente les résultats de l'étude IgGNITE de phase 2/3 sur le TAK-881 sous-cutané expérimental dans le déficit immunitaire primitif (DIP) à l'ESID 2026
businesswire.com
TAK
Hypersomnia - Drug Pipeline, Clinical Trials, and Competitive Landscape, 2026 | Orexin Agonists Open Strategic R&D, Licensing, and Partnership Opportunities
globenewswire.com
TAK
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1
businesswire.com
TAK
Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 2026
businesswire.com
TAK
ALK-Positive Non-Small Cell Lung Cancer Market, Epidemiology, and 7MM Forecast to 2036 | Market to Reach USD 3.37 Billion as Next-Generation ALK Inhibitors Drive Growth
globenewswire.com
PFE
TAK
PM360 2026 Trailblazer Awards Winners Announced: Top Companies, Marketers, CEOs, Products, and Initiatives Honored at Gala, Sept. 29th
prnewswire.com
ABT
AZN
CYTK
ARDX
LLY
REGN
NVO
KURA
NOV
BMY
MRK
ARGX
BMRN
TAK
VRTX
GSK
APMD
GKOS
GEN
LAR
ABBV
INCY
GILD
MOD
IQV
PFE
ALGN
SCL
Global Liver Cancer Diagnostics Market to Observe Impressive Growth at a CAGR of ~9% by 2034 | DelveInsight
globenewswire.com
LLY
MRK
GSK
BMY
AZN
PFE
NVO
REGN
RDHL
AGIO
INCY
CRBP
BMRN
VKTX
RIGL
DTIL
CRDF
BIIB
ALKS
EXAS
CLDX
SRPT
TGTX
ALNY
CHKP
TAK
HHS
SERV
GILD
HRMY
IONS
BH
FORM
JNJ
GEN
ABBV
AMGN
CRSP
CHRD
ADPT
IMUX
ALGN
EXEL
VRTX
Corus International Receives $6.4 Million Grant From Takeda to Reduce Climate-Related Health Risks in Nepal
businesswire.com
TAK
Synovial Sarcoma - Market Insights, Epidemiology, and Market Forecast - 2036 | TCR Cell Therapies Drive 7MM Growth and Investment Opportunities
globenewswire.com
TAK
Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill
businesswire.com
TAK